Patients who rely on the asthma inhaler Flovent will soon face challenges as GlaxoSmithKline (GSK) discontinues the branded medication and replaces it with an authorized generic version. This change, scheduled to take effect on January 1, has raised concerns among physicians who are worried that patients may encounter delays in transitioning to the new generic due to insurance coverage issues.
GSK’s move to discontinue the branded asthma inhaler Flovent comes as the pharmaceutical company shifts to an “authorized generic” version, identical to the original medication but lacking the recognizable branding. While physicians assure patients that the authorized generic will be just as effective as the branded drug, there is growing apprehension about the potential coverage hurdles with insurers.
The authorized generic is expected to work equally well for asthma patients, according to physicians. However, concerns arise as it appears that the generic may not be as widely covered by insurers as the branded drug. This could result in patients encountering difficulties in obtaining new prescriptions and navigating through insurance coverage obstacles during a time when respiratory viruses, such as the new Covid-19 variant, are on the rise.
Physicians are urging patients who rely on asthma inhalers to be proactive in addressing the impending changes. They advise patients to consult with their healthcare providers to obtain new prescriptions for the authorized generic, if necessary. Additionally, patients are encouraged to promptly address any insurance coverage issues to ensure a smooth transition to the new medication.
As pharmacies prepare to replace GSK’s asthma inhalers, known as “Flovent,” with the generic version, physicians emphasize the need for patients to take proactive steps to avoid disruptions in their treatment. The looming switch to the authorized generic raises concerns as some insurance companies have lower coverage for the generic medication. Therefore, patients are advised to address insurance coverage issues promptly to avoid any delays in accessing their necessary medications.
In light of this impending change, physicians stress the importance of early action for asthma patients who rely on inhalers. Amidst concerns over potential coverage challenges, it is crucial for patients to work closely with their healthcare providers and insurance companies to ensure a seamless transition to the authorized generic and minimize any interruptions in their asthma treatment.
